Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | BMC Veterinary Research

Figure 5

From: Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines

Figure 5

LLL12 synergizes with doxorubicin in canine OS cell lines. Proliferation curves and combination index graphs of canine (Abrams and OSA 16) OS cell lines after 24 hours of treatment with LLL12, doxorubicin, or both. For each cell line and treatment (LLL12 alone, DOXO alone, LLL12 + DOXO) there was a significant decreasing trend in cell proliferation with dose (*p < 0.001).

Back to article page